Guests/Speakers
Dr. Martin Edelman, MD – Fox Chase Cancer Center
Dr. Martin Edelman is Chair of Hematology-Oncology at Fox Chase Cancer Center and a nationally recognized thoracic oncologist. Throughout his career, he has helped advance treatment options for lung cancer patients through clinical research, immunotherapy development, and patient-centered care.
Jill Feldman – Lung Cancer Patient Advocate and Host
Jill Feldman is a lung cancer survivor, advocate, and nationally recognized voice in the lung cancer community. Through education and advocacy, she helps patients and families navigate diagnosis, treatment decisions, and survivorship.
Understanding Maintenance Therapy in Small Cell Lung Cancer
For people diagnosed with extensive-stage small cell lung cancer (ES-SCLC), the first rounds of treatment can be encouraging. Many patients see their tumors shrink quickly with chemotherapy and immunotherapy. But one of the biggest challenges of small cell lung cancer is that it often returns, sometimes within months.
In this episode of Hope With Answers, patient advocate Jill Feldman speaks with thoracic oncologist Dr. Martin Edelman about what happens after first-line treatment and why continuation therapy has become an important part of care.
What Is Maintenance Therapy?
After patients complete their initial chemotherapy, doctors may continue one component of treatment—most commonly immunotherapy—to help keep the cancer under control for as long as possible. Rather than starting something entirely new, the goal is often to continue a treatment that is already working.
“I wouldn’t look at so much as maintenance… as more of a continuation.”
— Dr. Martin Edelman
Why Does Small Cell Lung Cancer Return So Quickly?
Small cell lung cancer is one of the most genetically complex cancers physicians treat.
According to Dr. Edelman, years of exposure to tobacco carcinogens can create tumors with large numbers of mutations. Those mutations help cancer cells develop multiple ways to resist treatment, repair damage, and evade the immune system.
This complexity is one reason patients often experience an excellent initial response followed by recurrence months later.
Who Benefits Most From Continuation Therapy?
One of the biggest unanswered questions in small cell lung cancer is predicting who will experience long-term benefit from immunotherapy.
While physicians can identify certain factors associated with better outcomes—such as lower disease burden and the absence of extensive liver involvement—there is currently no laboratory test that reliably predicts which patients will have durable responses.
Dr. Edelman notes that immunotherapy has changed expectations for some patients, producing long-term responses that were rarely seen in the past.
Why Patients Should Ask About Clinical Trials Early
Clinical trials are not just an option after treatment stops working.
Dr. Edelman encourages patients to ask about clinical trials as early as possible—even at diagnosis. New immunotherapies, biomarkers, and treatment strategies are being studied today, and clinical trials remain the fastest path to improving outcomes for future patients.
“A clinical trial is appropriate from day one if one is available.”
— Dr. Martin Edelman
Balancing Time and Quality of Life
For many patients, treatment decisions are about more than extending survival. They are also about preserving quality of life.
Dr. Edelman emphasizes the importance of supportive care services, symptom management, and patient education. Patients should understand potential side effects, know when to contact their care team, and take advantage of available resources such as oncology nurses, palliative care specialists, and trusted organizations.
Questions to Ask Your Oncologist
1. Is continuation therapy right for me?
2. How long will I stay on immunotherapy?
3. What side effects should I expect?
4. Are there clinical trials available now?
5. What supportive care resources are available to me?
6. How will treatment affect my daily life and quality of life?
7. What happens if my cancer progresses?
Hope on the Horizon
While extensive-stage small cell lung cancer remains challenging, progress is being made.
Continuation immunotherapy is helping some patients experience longer-lasting responses, and researchers continue to develop new immunotherapies, biomarkers, and treatment approaches designed specifically for small cell lung cancer. Dr. Edelman believes there is genuine reason for optimism.
“We are improving outcomes.”
— Dr. Martin Edelman
